p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors

Triple-negative breast cancers (TNBCs) lack effective targeted therapies, and cytotoxic chemotherapies remain the standard of care for this subtype. Owing to their increased genomic instability, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are being tested against TNBCs. In particular, cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Cañedo, Eduardo Cepeda, Totten, Stephanie, Ahn, Ryuhjin, Savage, Paul, MacNeil, Deanna, Hudson, Jesse, Autexier, Chantal, Deblois, Genevieve, Park, Morag, Witcher, Michael, Ursini-Siegel, Josie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934920/
https://www.ncbi.nlm.nih.gov/pubmed/33470989
http://dx.doi.org/10.1172/jci.insight.138382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934920/
https://www.ncbi.nlm.nih.gov/pubmed/33470989
http://dx.doi.org/10.1172/jci.insight.138382

Ejemplares similares